CClinicalTrials.gg
CompletedNCT06973265Updated Aug 24, 2025

Effects of Transcutaneous Electrical Nerve Stimulation on Breast Surgery

An interventional study of TENS in Breast Cancer Surgery and Transcutaneous Electric Nerve Stimulation, sponsored by Seda Akutay. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Seda Akutay · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2024, registered May 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The aim of this randomized controlled trial was to evaluate the effects of transcutaneous electrical nerve stimulation (TENS) on postoperative pain, lymphedema development, shoulder range of motion, and quality of life in women undergoing breast cancer surgery after neoadjuvant chemotherapy. The main questions it aims to answer are:

Does TENS reduce postoperative pain? Does TENS prevent postoperative lymphedema? Does TENS increase postoperative shoulder range of motion? Does TENS improve postoperative quality of life? The researchers will compare the effects of TENS after breast surgery with a control group.

Participants will be assessed for pain, lymphedema development, and shoulder range of motion before surgery, on the first day after surgery, at the first month after surgery, and at the third month after surgery. Quality of life will be assessed before surgery, at the first month after surgery, and at the third month after surgery.

02

Conditions studied

  • Breast Cancer Surgery
  • Transcutaneous Electric Nerve Stimulation

Keywords

  • pain
  • lymphedema
  • Mastectomy
  • Mobility Limitation
  • Quality of Life
03

In context

Pain

2,226 studies on the registry are indexed under Pain; 917 are open to participants now.

This study's enrollment of 48 is below the median of 70 across 1,911 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

This is the only study on the registry with Seda Akutay as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Those whose primary cancer tissue is breast
  • ASA classification is between I and III
  • Having unilateral breast surgery

Exclusion criteria

Exclusion Criteria:

  • Those with cardiac problems and those using a pacemaker
  • Pregnant
  • Cognitively impaired
  • Disruption of skin integrity in the TENS application area
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    TENS group

    Patients in this group will receive TENS treatment for 1 month after surgery.

    Device: TENS

  • No intervention
    Control group

    Patients in this group do not receive TENS application after surgery.

Interventions

  • DeviceTENS

    After the surgery, 2 TENS electrodes will be placed on the inner part of the upper arm of the patient's arm on the side where surgery was performed, and the frequency will be 100 Hz, the pulse duration will be 100 µs and the amplitude will be adjusted so as not to cause muscle contraction, and a 20-minute TENS application will be performed.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    The Visual Analog Scale (VAS) scale will be used to assess pain intensity. It is a 10 cm line with connecting expressions on the left (no pain) and on the right (extreme pain). The patient is asked to mark the current pain level on the line. It means that the pain intensity increases as you move from left to right.

    Time frame: Until the end of 3 month

  2. Lymphedema severity

    A tape measure will be used to assess the severity of lymphedema. Measurements will be made bilaterally at 6 different points (Hand circumference, wrist, 15 cm below the elbow, 7,5 cm below the elbow, 7,5 cm above the elbow, 15 cm above the elbow )on the arm.

    Time frame: Until the end of 3 month

  3. Shoulder and arm mobility

    Shoulder range of motion (flexion, extension, abduction, internal rotation and external rotation angles of the arm) was measured with a goniometer.

    Time frame: Until the end of 3 month

Secondary outcomes

  1. Upper extremity functions

    The Quick Disability of the Arm, Shoulder and Hand (QuickDASH) Questionnaire and hand dynamometer will be used. In QuickDASH, a higher scores indicate a greater level of disability and severity, whereas, lower scores indicate a lower level of disability.

    Time frame: Preoperative period, postoperative 1 month and postoperative 3 month

  2. Cancer Related Quality of Life

    European Organization for Cancer Research and Treatment Quality of Life Questionnaire-30- EORTC QLQ-C30 will be used.

    Time frame: Preoperative period, postoperative 1 month and postoperative 3 month

07

Study locations

1 site
  • Erciyes University
    Kayseri, Kayseri 38260, Turkey (Türkiye)
08

References and documents

Publications

  • Akutay S, Yuceler Kacmaz H, Ceyhan O. The healing power of transcutaneous electrical nerve stimulation: a systematic review on its effects after breast surgery. Support Care Cancer. 2025 Jan 13;33(2):90. doi: 10.1007/s00520-024-09129-3. PubMed 39804405 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06973265
Lead sponsor
Seda Akutay
Collaborators
The Scientific and Technological Research Council of Turkey
Responsible party
Seda Akutay (Director, TC Erciyes University) — Sponsor-investigator
First posted
May 15, 2025
Start date
Sep 1, 2024
Primary completion
Jul 1, 2025
Completion
Aug 1, 2025
Last update
Aug 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion